Bnp Paribas Asset Management Holding S.A. Krystal Biotech, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 174 shares of KRYS stock, worth $32,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
174Holding current value
$32,899% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
314Shares Held
24.7MCall Options Held
418KPut Options Held
485K-
Black Rock Inc. New York, NY3.95MShares$746 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$534 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.66MShares$503 Million6.67% of portfolio
-
State Street Corp Boston, MA1.36MShares$256 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA942KShares$178 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.85B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...